- Home
- GGR vs KLRS Comparison
GGR vs KLRS Comparison
Compare GGR & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GGR | KLRS |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 92.8M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GGR | KLRS |
|---|---|---|
| Price | $2.97 | $2.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 16.0K | ★ 52.1K |
| Earning Date | 05-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $165,000.00 |
| Revenue This Year | $5.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $3.02 |
| 52 Week High | $6.21 | $11.88 |
Technical Indicators
Market Signals| Indicator | GGR | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 59.93 | 25.18 |
| Support Level | $2.96 | N/A |
| Resistance Level | $3.42 | $4.37 |
| Average True Range (ATR) | 0.14 | 0.19 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 90.57 | 3.03 |
Price Performance
Historical ComparisonAbout GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.